Liver health may change how a promising cancer drug works in the body
NCT ID NCT07677358
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study investigates how the experimental cancer drug atirmociclib is processed by the body in people with mild, moderate, or severe liver disease compared to those with healthy livers. Participants receive a single oral dose of the drug, and blood samples are taken over time to measure drug levels. The goal is to see if liver impairment alters how the drug behaves, which could guide safer dosing for patients with liver issues. The study involves about 28 adults and lasts roughly 9 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atirmociclib
What this could lead to
If successful, this study could help doctors determine the right dose of atirmociclib for patients with liver problems, making the drug safer to use.
What could go wrong
This is an early-phase study with only 28 participants, so results may not apply to everyone. The drug may still cause side effects regardless of liver function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Floridian Clinical Research
Miami Lakes, Florida, 33016, United States
-
Genesis Clinical Research
Tampa, Florida, 33603, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States